Patient perspectives on antipsychotic treatments and their association with clinical outcomes

References

• GaebelWPietzckerAOne-year outcome of schizophrenic patients – the interaction of chronicity and neuroleptic treatmentPharmacopsychiatry1985182352392861609
   PubMed Web of Science ®Google Scholar
• Novak-GrubicVTavcarRPredictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorderEur Psychiatry20021714815412052575
   PubMed Web of Science ®Google Scholar
• MullinsCDObeidatNACuffelBJNaradzayJLoebelADRisk of discontinuation of atypical antipsychotic agents in the treatment of schizophreniaSchizophr Res20089881517596914
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHFariesDEZhuBErnstFRSwartzMSSwansonJWMedication adherence and long-term functional outcomes in the treatment of schizophrenia in usual careJ Clin Psychiatry20066745346016649833
   PubMed Web of Science ®Google Scholar
• LindenmayerJPLiu-SeifertHKulkarniPMMedication non-adherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior responseJ Clin Psychiatry20097099099619497244
   PubMed Web of Science ®Google Scholar
• Ayuso-GutiérrezJLdel Río VegaJMFactors influencing relapse in the long-term course of schizophreniaSchizophr Res1997281992069468354
   PubMed Web of Science ®Google Scholar
• LindströmEBingeforsKPatient compliance with drug therapy in schizophrenia. Economic and clinical issuesPharmacoeconomics20001810612411067646
   PubMed Web of Science ®Google Scholar
• WeidenPJKozmaCGroggALocklearJPartial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPsychiatr Serv20045588689115292538
   PubMed Web of Science ®Google Scholar
• JanssenBGaebelWHaerterMKomaharadiFLindelBWeinmannSEvaluation of factors influencing medication compliance in inpatient treatment of psychotic disordersPsychopharmacology200618722923616710714
   PubMed Web of Science ®Google Scholar
• OlfsonMMechanicDHansellSBoyerCAWalkupJWeidenPJPredicting medication noncompliance after hospital discharge among patients with schizophreniaPsychiatr Serv20005121622210655006
   PubMed Web of Science ®Google Scholar
• VorugantiLCorteseLOwyeumiLSwitching from conventional to novel antipsychotic drugs: Results of a prospective naturalistic studySchizophr Res20025720120812223251
   PubMed Web of Science ®Google Scholar
• BradfordDWPerkinsDOLiebermanJAPharmacological management of first-episode schizophrenia and related nonaffective psychosesDrugs2003632265228314524730
   PubMed Web of Science ®Google Scholar
• ThomasPAlptekinKGheorgheMMauriMOlivaresJMRiedelMManagement of patients presenting with acute psychotic episodes of schizophreniaCNS Drugs20092319321219320529
   PubMed Web of Science ®Google Scholar
• PolliceRTomassiniAMalavoltaMSubjective and psychopathological response in patients under different antipsychotic treatments: Are there differences in real clinical practiceJ Biol Regul Homeost Agents200822839118394321
   PubMed Web of Science ®Google Scholar
• RoccaPCrivelliBMarinoFMonginiTPortaleoneFBogettoFCorrelations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophreniaCompr Psychiatry20084917017618243890
   PubMed Web of Science ®Google Scholar
• Schennach-WolffRJägerMSeemullerFAttitude towards adherence in patients with schizophrenia at dischargeJ Psychiatr Res2009431294130119505697
   PubMed Web of Science ®Google Scholar
• DiazENeuseESullivanMCPearsallHRWoodsSWAdherence to conventional and atypical antipsychotics after hospital dischargeJ Clin Psychiatry20046535436015096075
   PubMed Web of Science ®Google Scholar
• BeckerMHMaimanLASociobehavioral determinants of compliance with health and medical care recommendationsMed Care19751310241089182
   PubMed Web of Science ®Google Scholar
• FentonWSBlylerCRHeinssenRKDeterminants of medication compliance in schizophrenia: empirical and clinical findingsSchizophr Bull1997236376519366000
   PubMed Web of Science ®Google Scholar
• PerkinsDOAdherence to antipsychotic medicationsJ Clin Psychiatry199960253010548139
   PubMed Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull1987132612763616518
   PubMed Web of Science ®Google Scholar
• HoganTPAwadAGEastwoodRA self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validityPsychol Med1983131771836133297
   PubMed Web of Science ®Google Scholar
• KeefeRSEYoungCARockSLPurdonSEGoldJMBreierAthe HGGN Study Group, 2006One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophreniaSchizophr Res20068111516202565
   PubMed Web of Science ®Google Scholar
• BreierABergPHThakoreJHOlanzapine versus ziprasidone: Results of a 28-week double-blind study in patients with schizophreniaAm J Psychiatry20051621879188716199834
   PubMed Web of Science ®Google Scholar
• KinonBJAhlJRotelliMDMcMullenEEfficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophreniaAm J Emerg Med20042218118615138953
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders4th EditionWashington, DCAmerican Psychiatric Association1994
   Google Scholar
• OverallJEGorhamDRThe Brief Psychiatric Rating ScalePsychol Rep196210799812
   Web of Science ®Google Scholar
• GuyWECDEU Assessment Manual for Psychopharmacology, Revised. Publication ADM 76–338Bethesda, MDUnited States Department of Health, Education, and Welfare1976
   Google Scholar
• World Medical Association, 2000Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects As adopted by the 18th General Assembly; Helsinki, Finland; Jun 1964; and amended by the 52nd General Assembly; Edinburgh, Scotland; Oct 2000.
   Google Scholar
• DavisJMChenNThe effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: Combined results of the North American and international trialsJ Clin Psychiatry20016275777111816864
   PubMed Web of Science ®Google Scholar
• HaroJMNovickDSuarezDRocaMAntipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO studyJ Psychiatr Res20094326527318644606
   PubMed Web of Science ®Google Scholar
• KinonBJAscher-SvanumHAdamsDHChenLThe temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trialsJ Clin Psychopharmacol20082854454918794651
   PubMed Web of Science ®Google Scholar
• KupperZTschacherWLack of concordance between subjective improvement and symptom change in psychotic episodesBr J Clin Psychol200847759317927846
   PubMed Web of Science ®Google Scholar
• Liu-SeifertHHoustonJPAdamsDHKinonBJAssociation of acute symptoms and compliance attitude in noncompliant patients with schizophreniaJ Clin Psychopharmacol20072739239417632224
   PubMed Web of Science ®Google Scholar
• PerkinsDOJohnsonJLHamerRMHGDH Research GroupPredictors of antipsychotic medication adherence in patients recovering from a first psychotic episodeSchizophr Res200683536316529910
   PubMed Web of Science ®Google Scholar
• KarowACzekallaJDittmannRWAssociation of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophreniaJ Clin Psychiatry200768758017284133
   PubMed Web of Science ®Google Scholar
• StankovićZBritvicDVukovicOIlleTTreatment compliance of outpatients with schizophrenia: Patient’s attitudes, demographic, clinical and therapeutic variablesPsychiatr Danub200820425218376330
   PubMed Web of Science ®Google Scholar
• MohamedSRosenheckRMcEvoyJSwartzMStroupSLiebermanJACross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophreniaSchizophr Bull20093533634618586692
   PubMed Web of Science ®Google Scholar
• GharabawiGMGreenspanARupnowMFTReduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trialBMC Psychiatry200664517054789
   PubMed Web of Science ®Google Scholar
• FleischhackerWWMcQuadeRDMarcusRNArchibaldDSwaninkRCarsonWHA double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophreniaBiol Psychiatry20096551051718986646
   PubMed Web of Science ®Google Scholar
• KinonBJLipkovichIEdwardsSBAdamsDHAscher-SvanumHSirisSGA 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptomsJ Clin Psychopharmacol20062615716216633144
   PubMed Web of Science ®Google Scholar
• StroupTSLiebermanJAMcEvoyJPfor the CATIE InvestigatorsEffectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychoticAm J Psychiatry200616361162216585435
   PubMed Web of Science ®Google Scholar
• BurtonSCStrategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of useJ Psychiatr Pract20051136937816304505
   PubMedGoogle Scholar
• ByerlyMJFisherRCarmodyTRushAJA trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorderJ Clin Psychiatry200566997100116086614
   PubMed Web of Science ®Google Scholar
• PatelMXde ZoysaNDavidASA cross-sectional study of patients’ perspectives on adherence to antipsychotic medication: Depot versus oralJ Clin Psychiatry2008691548155619192437
   PubMed Web of Science ®Google Scholar
• van PuttenTWhy do schizophrenic patients refuse to take their drugsArch Gen Psychiatry19743167724151750
   PubMed Web of Science ®Google Scholar
• AwadAGVorugantiLNPNew antipsychotics, compliance, quality of life, and subjective tolerability – are patients better offCan J Psychiatry20044929730215198465
   PubMed Web of Science ®Google Scholar
• KinonBJLiu-SeifertHAdamsDHCitromeLDifferential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophreniaJ Clin Psychopharmacol20062663263717110821
   PubMed Web of Science ®Google Scholar
• KinonBJNoordsyDLLiu-SeifertHGulliverAHAscher-SvanumHKollack-WalkerSRandomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioningJ Clin Psychopharmacol20062645346116974184
   PubMed Web of Science ®Google Scholar
• Liu-SeifertHAdamsDHKinonBJDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: A pooled post-hoc analysis of four atypical antipsychotic drugsBMC Med200532116375765
   PubMed Web of Science ®Google Scholar
• MasandPSNarasimhanMImproving adherence to antipsychotic pharmacotherapyCurr Clin Pharmacol20061475618666377
   PubMedGoogle Scholar
• LiebermanJAStroupTSMcEvoyJPfor the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) InvestigatorsEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med20053531209122316172203
   PubMed Web of Science ®Google Scholar